Posts

Showing posts from November, 2020

us hospitals lists

Image
When public mention modern medicine, precision plays one of the most crucial roles and people’s lives are literally dependent on it. Hence, any researches related to medicine are necessary to comply with the highest standards. The problem nowadays is that any conclusions of researches can be shared online and used as a reference without being properly verified and approved. Mikhail (Misha) Blagosklonny of Oncotarget perfectly understood this problem and tried to come up with an alternative solution. That’s how a weekly oncology-focused research journal called “Oncotarget” has been established back in 2010. The main principle of this journal is based on Altmetric scores that are used as a quality measure. That allows both readers and authors to quality-check publications with Altmetric Article Reports that create “real-time feedback containing data summary related to a particular publication". Oncotarget website provides a full publications list with respective scores above 100

Oncotarget: Genomic markers of midostaurin drug sensitivity in leukemia patients

  Oncotarget   Volume 11 ,   Issue 29   reported that   acute myeloid leukemia   is a heterogeneous malignancy with the most common genomic alterations in NPM1, DNMT3A, and FLT3. Midostaurin was the first FLT3 inhibitor FDA approved for AML and is standard of care for FLT3 mutant patients undergoing induction chemotherapy. As there is a spectrum of response, we hypothesized that biological factors beyond FLT3 could play a role in drug sensitivity and that select FLT3-ITD negative samples may also demonstrate sensitivity. The Oncotarget authors performed an ex vivo drug sensitivity screen on primary and relapsed AML samples with corresponding targeted sequencing and RNA sequencing. They observed a correlation between FLT3-ITD mutations and midostaurin sensitivity as expected and observed KRAS and TP53 mutations correlating with midostaurin resistance in FLT3-ITD negative samples. Further, they identified genes differentially expressed in sensitive vs. resistant samples independent of F

hospitals in us

Image
When general population mention modern medicine, accuracy plays one of the most important roles and human lives are literally dependent on it. Likewise, any researches pertaining to medicine are necessary to comply with the top standards. The issue nowadays is that any recommendations of researches can be posted online and used as a reference without being properly verified and validated. Mikhail (Misha) Blagosklonny of Oncotarget perfectly understood this problem and tried to develop an alternative solution. That’s how a weekly oncology-focused research journal called “Oncotarget” has been established back in 2010. The main principle of this journal is based on Altmetric scores that are used as a quality indicator. That assists both readers and authors to quality-check publications with Altmetric Article Reports that provide “real-time feedback containing data summary related to a particular publication". Oncotarget website has a complete publications list with respective sco

Oncotarget: Paradox breaker BRAF inhibitors in BRAF mutant colorectal cancer

  Oncotarget   Volume 11 ,   Issue 34   features Figure 1, " BRAF inhibitor-induced changes in cell viability, " by Pickles, et which reported that the BEACON CRC trial demonstrated a survival advantage over chemotherapy for a combination of targeted agents comprising the potent BRAF inhibitor   encorafenib   together with   cetuximab   and   binimetinib . Resistance to BRAF inhibition in CRC arises in part through the generation and activation of RAF dimers resulting in MEK-ERK pathway reactivation. The Oncotarget authors analyzed whether paradox breakers reduce pathway reactivation and so have enhanced potency compared with encorafenib in BRAF mutant CRC. However, dose-response curves for encorafenib and PLX8394 were similar and there were no significant differences in the degree of pathway reactivation. To their knowledge, these data represent the first comparative data of encorafenib and paradox breaker inhibitors in BRAF mutant CRC. Dr. Gary W. Middleton from The Institu

hospitals in us

Image
When people discuss contemporary medicine, precision plays one of the most significant roles and human lives are literally dependent on it. Hence, any researches pertaining to medicine are necessary to comply with the top standards. The problem today is that any outcomes of researches can be published online and used as a reference without being properly verified and approved. Mikhail (Misha) Blagosklonny of Oncotarget clearly understood this problem and decided to develop an alternative solution. That’s how a weekly oncology-focused research journal named “Oncotarget” has been founded back in 2010. The main principle of this journal is based on Altmetric scores that are used as a quality measure. That helps both readers and authors to quality-check publications with Altmetric Article Reports that provide “real-time feedback containing data summary related to a particular publication". Oncotarget website provides a complete publications list with respective scores above 100 as

clinic list in us

Image
When general population mention today’s medicine, precision plays one of the most crucial roles and people’s lives are literally dependent on it. Likewise, any researches pertaining to medicine are required to comply with the top standards. The challenge nowadays is that any recommendations of researches can be posted online and used as a reference without being adequately checked and approved. Mikhail (Misha) Blagosklonny of Oncotarget clearly understood this challenge and attempted to develop an alternative solution. That’s how a weekly oncology-focused research journal named “Oncotarget” has been founded back in 2010. The key principle of this journal is related to Altmetric scores that are used as a quality indicator. That allows both readers and authors to verify publications with Altmetric Article Reports that create “real-time feedback containing data summary related to a particular publication". Oncotarget website has a complete publications list with corresponding sco

Oncotarget: Melatonin increases overall survival of prostate cancer patients FOR IMMEDIATE RELEASE

  Oncotarget recently published "Melatonin increases overall survival of prostate cancer patients with poor prognosis after combined hormone radiation treatment" which reported that a retrospective study included 955 patients of various stages of prostate cancer who received combined hormone radiation treatment from 2000 to 2019. Comprehensive statistical methods were used to analyze the overall survival rate of PCa patients treated with melatonin in various prognosis groups. The overall survival rate of PCa patients with favorable and intermediate prognoses treated or not treated with melatonin was not statistically significantly different. In the poor prognosis group , the median overall survival in patients taking the drug was 153.5 months versus 64.0 months in patients not using it. In a multivariate analysis, melatonin administration proved to be an independent prognostic factor and reduced the risk of death of PCa patients by more than twice. The multicomponent antitu

us hospitals lists

Image
When general population mention today’s medicine, precision plays one of the most crucial roles and human lives are directly dependent on it. Likewise, any researches related to medicine are required to comply with the top standards. The problem today is that any conclusions of researches can be shared online and used as a reference without being adequately verified and approved. Mikhail (Misha) Blagosklonny of Oncotarget perfectly understood this problem and attempted to develop an alternative solution. That’s how a weekly oncology-focused research journal named “Oncotarget” has been founded back in 2010. The key principle of this journal is based on Altmetric scores that are used as a quality indicator. That helps both readers and authors to verify publications with Altmetric Article Reports that provide “real-time feedback containing data summary related to a particular publication". Oncotarget website demonstrates a complete publications list with respective scores higher

MEK - многообещающая мишень при базальном подтипе рака мочевого пузыря

Oncotarget , недавно опубликованный в статье Merrill и соавт., « MEK является многообещающей мишенью для базального подтипа рака мочевого пузыря ». в котором сообщается, что, хотя существует множество ресурсов для скрининга на лекарства клеточных линий рака мочевого пузыря в 2D-культуре, широко признано, что скрининг в 3D-культуре более характерен для реакции in vivo. Чтобы удовлетворить потребность в трехмерном скрининге лекарств для линий клеток рака мочевого пузыря, авторы провели скрининг 17 линий клеток рака мочевого пузыря, используя библиотеку из 652 исследуемых малых молекул и 3 клинически значимых комбинаций лекарств в трехмерной клеточной культуре. Их цель состояла в том, чтобы идентифицировать соединения и классы соединений, эффективных при раке мочевого пузыря. Используя установленные геномные и транскриптомные данные для этих клеточных линий рака мочевого пузыря, они коррелировали геномные молекулярные параметры с лекарственной реакцией, чтобы идентифицировать потенциа

clinics in us

Image
When public mention contemporary medicine, precision plays one of the most significant roles and people’s lives are directly dependent on it. Hereby, any researches pertaining to medicine are required to meet the top standards. The challenge today is that any outcomes of researches can be published online and used as a reference without being thoroughly verified and approved. Mikhail (Misha) Blagosklonny of Oncotarget clearly understood this challenge and decided to create an alternative solution. That’s how a weekly oncology-focused research journal called “Oncotarget” has been founded back in 2010. The key principle of this journal is based on Altmetric scores that are used as a quality indicator. That allows both readers and authors to validate publications with Altmetric Article Reports that provide “real-time feedback containing data summary related to a particular publication". Oncotarget website has a full publications list with corresponding scores above 100 as well as

Is Oncotarget a good journal?

Image
When general population discuss today’s medicine, precision plays one of the most crucial roles and people’s lives are directly dependent on it. Hereby, any researches related to medicine are required to meet the top standards. The problem nowadays is that any recommendations of researches can be shared online and used as a reference without being adequately checked and approved. Mikhail (Misha) Blagosklonny of Oncotarget perfectly understood this issue and decided to develop an alternative solution. That’s how a weekly oncology-focused research journal called “Oncotarget” has been established back in 2010. The main principle of this journal is related to Altmetric scores that are used as a quality indicator. That allows both readers and authors to quality-check publications with Altmetric Article Reports that provide “real-time feedback containing data summary related to a particular publication". Oncotarget website provides a complete publications list with respective scores